Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus
Rendy Andriyanto
Gotrade Team
Reviewed by Gotrade Internal Analyst
Share this article
Gotrade News - Biotech stocks delivered a mixed session as Moderna secured Ebola vaccine funding while Summit Therapeutics surged 10.43% on Phase 3 trial data. Alignment Healthcare slumped 13.19% on a Barclays downgrade, and Iovance Biotherapeutics drew fresh value debate from analysts.
The split tape reflected investor focus on clinical catalysts over near-term analyst sentiment in healthcare names. Trial results and government partnerships overpowered bearish price targets across several mid-cap biotech tickers on Monday.
Key Takeaways
Moderna receives up to $50 million from CEPI to develop a Bundibugyo Ebola vaccine using mRNA technology.
Summit Therapeutics jumped 10.43% on positive Phase 3 Ivonescimab data despite Bernstein's underperform rating.
Alignment Healthcare fell 13.19% as Barclays cut its price target to $16 from $19.
According to Investing.com, the Coalition for Epidemic Preparedness Innovations committed $60 million in total funding for a Bundibugyo Ebola vaccine effort. Moderna (MRNA) will receive up to $50 million, while Oxford and Serum Institute share $8.6 million and IAVI gets an initial $3.2 million.
The outbreak in the Democratic Republic of Congo has produced 282 confirmed cases and roughly 1,100 suspected cases, with 9 more confirmed in Uganda. No approved BDBV vaccines or treatments currently exist, raising the strategic value of Moderna's mRNA platform.
CEO Stephane Bancel said the goal is to move as fast as possible without compromising safety standards. CEPI head Richard Hatchett indicated vaccine candidates could be ready for trials within a couple of months.
Iovance Value Debate and ALHC Downgrade
According to The Motley Fool, Iovance Biotherapeutics is down nearly 80% over five years but up 50% year-to-date. The stock traded at $3.96, off 3.42%, with a market capitalization of roughly $1.8 billion.
Iovance focuses on tumor-infiltrating lymphocyte (TIL) therapy, with flagship melanoma drug Amtagvi now commercialized. Management has projected potential peak annual sales exceeding $1 billion as adoption widens.
Q1 2026 revenue reached $71 million, missing the $75.6 million consensus, though sales rose 45% year-over-year. The company holds $319 million in cash, funding operations through 2028, which the Fool framed as suitable for aggressive investors.
As reported by Insider Monkey, Alignment Healthcare fell 13.19% to close at $13.30, extending a seven-day losing streak. Barclays cut the price target to $16 from $19 while keeping an equal weight rating.
ALHC has now declined 32% in May alone and 32.6% year-to-date, with investors awaiting business updates at the Goldman Sachs Global Healthcare Conference on June 9. Raymond James also trimmed its target last month while maintaining a buy recommendation.
Per Insider Monkey, Summit Therapeutics (SMMT) closed up 10.43% at $15.71, defying a bearish Bernstein note. Bernstein reaffirmed an underperform rating with a $7.70 target, implying roughly 51% downside.
Over the weekend Summit reported positive Phase 3 results for Ivonescimab, developed with Akeso Inc., in lung cancer patients. The combination showed a 34% reduction in death risk versus tislelizumab plus chemotherapy in the Harmoni-6 study.
Bernstein cited concerns about a non-statistically significant overall survival trend, but traders rewarded the trial readout over analyst caution. The session highlighted how clinical milestones can overpower sell-side skepticism in mid-cap biotech names like BioNTech (BNTX) peers.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
